Dysfunctional HDL Takes Its Toll in Chronic Kidney Disease  by Moore, Kathryn J. & Fisher, Edward A.
Immunity
Previewsfrom other tissues or similar tumors
initiated by other oncgenic-driver muta-
tions, as well as whether this specific
population or simply monocyte-derived
CD11b+ inflammatory DCs in general are
important.
Several immune-based therapies have
recently been approved for clinical use,
primarily for refractory metastatic dis-
ease, with many clinical trials underway
examining efficacy at earlier stages in
conjunction with standard-of-care CTX.
As noted by the authors, it remains un-
clear whether CTX alone can elicit a de
novo T cell response or instead is reacti-
vating a suppressed response that, in
conjunction with the enhanced suscepti-
bility of CTX-treated tumor cells to killing
by granzyme B, is able to limit tumor
growth (Ramakrishnan et al., 2010). Iden-628 Immunity 38, April 18, 2013 ª2013 Elsevtifying which of these possibilities is
accuratemay assist with the development
of future immune-based therapies in the
clinical arena.
REFERENCES
Chekeni, F.B., Elliott, M.R., Sandilos, J.K., Walk,
S.F., Kinchen, J.M., Lazarowski, E.R., Armstrong,
A.J., Penuela, S., Laird, D.W., Salvesen, G.S.,
et al. (2010). Nature 467, 863–867.
Ciampricotti, M., Hau, C.S., Doornebal, C.W.,
Jonkers, J., and de Visser, K.E. (2012). Nat. Med.
18, 344–346.
DeNardo, D.G., Brennan, D.J., Rexhepaj, E.,
Ruffell, B., Shiao, S.L., Madden, S.F., Gallagher,
W.M., Wadhwani, N., Keil, S.D., Junaid, S.A.,
et al. (2011). Cancer Discov 1, 54–67.
Duffy, D., Perrin, H., Abadie, V., Benhabiles, N.,
Boissonnas, A., Liard, C., Descours, B., Reboul-
leau, D., Bonduelle, O., Verrier, B., et al. (2012).
Immunity 37, 917–929.ier Inc.Edelson, B.T., Kc, W., Juang, R., Kohyama, M.,
Benoit, L.A., Klekotka, P.A., Moon, C., Albring,
J.C., Ise, W., Michael, D.G., et al. (2010). J. Exp.
Med. 207, 823–836.
Ma, Y., Adjemian, S., Mattarollo, S.R., Yamazaki,
T., Aymeric, L., Yang, H., Catani, J.P.P., Hannani,
D., Duret, H., Steegh, K., et al. (2013). Immunity
38, this issue, 729–741.
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S.R.,
Delahaye, N.F., Pereira, P., Boucontet, L., Apetoh,
L., Ghiringhelli, F., Casares, N., et al. (2011). J. Exp.
Med. 208, 491–503.
Ramakrishnan, R., Assudani, D., Nagaraj, S.,
Hunter, T., Cho, H.I., Antonia, S., Altiok, S., Celis,
E., and Gabrilovich, D.I. (2010). J. Clin. Invest.
120, 1111–1124.
Youn, J.I., Kumar, V., Collazo, M., Nefedova, Y.,
Condamine, T., Cheng, P., Villagra, A., Antonia,
S., McCaffrey, J.C., Fishman, M., et al. (2013).
Nat. Immunol. 14, 211–220.
Zitvogel, L., Kepp, O., and Kroemer, G. (2011).
Nat Rev Clin Oncol 8, 151–160.Dysfunctional HDL Takes Its Toll
in Chronic Kidney DiseaseKathryn J. Moore1,* and Edward A. Fisher1
1Marc and Ruti Bell Vascular Biology and Disease Program, Leon H. Charney Division of Cardiology, Department of Medicine,
New York University School of Medicine, New York, NY 10029, USA
*Correspondence: kathryn.moore@nyumc.org
http://dx.doi.org/10.1016/j.immuni.2013.03.006
Why patients with chronic kidney disease have elevated cardiovascular risk remains elusive. In this issue
of Immunity, Speer et al. (2013) show that natural modification of high density lipoprotein promotes hyperten-
sion through a toll-like receptor-dependent mechanism.Chronic kidney disease (CKD) afflicts mil-
lions of people, with the majority of these
patients eventually dying, not from renal
failure but from accelerated cardiovas-
cular disease (CVD). Notably, although
this population suffers from comorbid
conditions known to increase CVD risk,
such as diabetes and hypertension, their
dramatically increased cardiovascular
mortality cannot be fully explained by
these and other ‘‘traditional’’ risk factors,
such as age, gender, smoking, choles-
terol levels, obesity, and physical inac-
tivity (Beddhu et al., 2007). Animal models
are concordant with the clinical data. For
example, when renal disease is intro-
duced into mouse models, there is accel-erated progression or impaired regression
of atherosclerosis (e.g., Ponda et al.,
2010).
While practitioners await progress in
filling in the gaps in the mechanisms
underlying the increased risk of CVD in
CKD patients, current therapy necessarily
is based on regimens used in the general
population. Unfortunately, the risk reduc-
tion is frequently below that achieved in
non-CKD patients, which already is sub-
optimal. For example, in hemodialysis
patients, statins are able to impressively
lower low density lipoprotein (LDL)
cholesterol, but unlike other at-risk popu-
lations who are expected to have 30%–
40% reductions in CVD events, thesepatients do not experience improved
survival.
This incomplete success of current
clinical therapies in the general popula-
tion, as well as in those with specific sub-
populations, such as those with CKD, has
called attention to the potential role of
HDL, the so-called ‘‘good cholesterol’’ to
reduce the substantial level of residual
CVD risk. The basis for this hope, as we
recently reviewed (Hewing et al., 2012),
has been numerous observational studies
that have demonstrated an inverse rela-
tionship between levels of HDL-choles-
terol (HDL-C) and CVD risk. Yet a spate
of recent studies, both genetic and
interventional, has raised the issue that
Figure 1. Elevated SDMA in Chronic Kidney Disease
Generates Dysfunctional HDL
In CKD, SDMA accumulates in HDL, rendering this normally
protective lipoprotein dysfunctional. SDMA-HDL or HDLCKD
initiates TLR2 signaling on endothelial cells that results in
increased superoxide production and reduced NO bioavail-
ability and, consequently, increased blood pressure.
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PreviewsHDL-C might be more of a risk
marker and not a risk factor of
CVD. Rather, the consensus has
been shifting to HDL function being
the key factor that is protective
against CVD. Historically, the most
frequently studied function of HDL
in regard to CVD has been its ability
to remove excess cholesterol from
cells, particularly from those in
atherosclerotic plaques, for return
to the liver in a process called re-
verse cholesterol transport (RCT).
Indeed, in a small but influential
clinical study, this ability (measured
in vitro using patient samples) was
better correlated with CVD events
than any other parameter measured
(Khera et al., 2011).
In this issue of Immunity, Speer
et al. (2013) report that the HDL
from patients with CKD becomes
dysfunctional, altering the protec-
tive properties of this lipoprotein.
Though less frequently studied
than its role in RCT, another poten-
tial beneficial function of HDL is its
ability to promote endothelial func-
tion. As Speer et al. (2013) note,endothelial dysfunction has been linked
in preclinical and clinical studies to
increased risk of CVD and to its underlying
contributory pathophysiologies, including
atherosclerosis, hypertension, and dia-
betes. Through its anti-inflammatory and
proreparative actions, HDL is thought to
protect the integrity and function of the
endothelium. However, Speer et al
demonstrate that HDL from CKD patients
(HDLCKD) not only loses its vasoprotective
properties but also is in fact rendered a
damaging particle that promotes endo-
thelial dysfunction, hypertension, and
inflammation. The authors identify the
naturally produced compound symmetric
dimethylarginine (SDMA), which is
elevated in the plasma of patients with
CKD, as the culprit associated with HDL
responsible for the adverse vascular ac-
tions of this harmful lipoprotein.
In healthy individuals, HDL stimulates
endothelial nitric oxide (NO) production,
which serves as a critical stimulus to
preserving endothelial function. Instead,
HDLCKD or healthy HDL supplemented
with SDMA (HDLSDMA), increased the pro-
duction of reactive oxygen species (ROS)
and reduced the availability of atheropro-
tective endothelial NO, promoting vaso-constriction, inflammatory activation,
and hindering endothelial repair. Notably,
these effects of SDMA-containing HDL
were not mediated by the major endo-
thelial HDL-binding protein scavenger re-
ceptor B-I (SR-BI) but rather through
recognition by Toll-like receptor 2 (TLR2)
(Figure 1). TLRs are pattern-recognition
receptors that play an integral role in the
innate immune response to both path-
ogen-associated molecular patterns and
endogenous danger-associated molec-
ular patterns. TLR2, in particular, has
been associated with endothelial dys-
function after coronary endothelial injury
and with the development of atheroscle-
rosis (Favre et al., 2007; Mullick et al.,
2008). However, the mechanisms under-
lying TLR2 activation in these sterile
inflammatory conditions remain largely
unknown.
The selective inhibition or genetic defi-
ciency of TLR2 abrogated the adverse
effects of HDLCKD and HDLSDMA on endo-
thelial NO, hypertension, and endothelial
repair. Interestingly, TLR2-mediated re-
sponses to SDMA did not require either
of its known heterodimeric signaling
partners, TLR1 or TLR6. Although it is
possible that TLR1 and TLR6 serve redun-Immunity 38, Adant roles in the response to SDMA,
TLR2 might also potentially partner
with another TLR or function in a
homodimeric fashion in this context.
Furthermore, although NF-kB acti-
vation is considered one of the
most potent downstream effects of
TLR2 engagement, HDLCKD and
HDLSDMA failed to activate NF-kB
in endothelial cells. Rather, TLR2
signaling by these ligands induced
nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase activ-
ity to promote endothelial super-
oxide production. This alternative
TLR2 signaling pathway could also
be activated by microbial ligands of
TLR2, including Pam3CSK4, and
was characterized by reduced
phosphorylation of the kinase Akt
at Ser473 and an associated inhibi-
tory phosphorylation of endothelial
NO synthase. Consistent with
previous observations that reduced
NO bioavailability coupled with
increased superoxide production
impairs critical endothelial func-
tions, HDLCKD and HDLSDMA in-
hibited endothelial repair in vitroand in a mouse carotid injury model.
These detrimental effects of HDLCKD and
HDLSDMA were absent in TLR2-deficient
mice, confirming the essential role of this
innate immune receptor in mediating the
effects of this dysfunctional HDL. On the
basis of these findings in mice, therapeu-
tic strategies that would block the actions
of SDMA or induction of the alternative
TLR2 signaling pathway, while leaving
TLR2-dependent NF-kB activation intact,
would be predicted to have clinical benefit
in CKD patients.
In summary, this study by Speer et al.
provides several important insights into
potential mechanisms contributing to
elevated risk of CVD in patients with
CKD. First, it identifies SDMA as the caus-
ative factor in CKD that transforms physi-
ological HDL into an abnormal lipoprotein
capable of inducing endothelial dysfunc-
tion. This previously overlooked isomer
of asymmetric dimethylarginine (ADMA),
an endogenous inhibitor of eNOS, accu-
mulates in HDL with even mild CKD, and
thus therapeutic targeting of this molecule
might offer treatment for early stages of
disease. Second, it identifies SDMA as
an endogenous ligand of TLR2 that
signals via a nonconventional pathway topril 18, 2013 ª2013 Elsevier Inc. 629
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Previewsincrease reactive oxygen species and
directly regulate blood pressure, thereby
linking innate immunity, endothelial
dysfunction, and hypertension. There are
a number of questions to be addressed
in future studies, including those concern-
ing basic science (such as why SDMA is
elevated in CKD, why elevated ADMA,
also seen in CKD, does not cause the
same dysfunction, and how TLR2 sig-
naling proceeds in the absence of TLR1
and/or TLR6), as well as those related to
the clinical implications. For example, it
is well established that atherosclerosis
begins early in life and, to date, all of the
risk factors in adults modulate the pro-
gression of the disease in the teenage
years (McGill et al., 2000). It is also known
that the earlier in life risk factor reduction
is achieved, the greater the decrease in
life-long risk of CVD disease (e.g., Cohen
et al., 2006). With this in mind, finding630 Immunity 38, April 18, 2013 ª2013 ElsevSDMA-modified HDL in children with
CKD raises the question that if further clin-
ical studies support SDMA and the asso-
ciated pathway as important therapeutic
targets, how early in life should one begin
to avoid paying the toll?REFERENCES
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It has been unclear whether an innate lymphoid cell (ILC) counterpart to the T helper 1 cell type exists. New
studies, including Fuchs et al. (2013) in this issue of Immunity, identify T-bet+IFN-g+ ILC1 that accumulate in
the inflamed intestine of IBD patients.A burgeoning body of recent literature has
described a variety of innate lymphoid cell
(ILC) populations arising from a common
lymphoid progenitor, that lack rearranged
antigen receptors and do not express
myeloid or dendritic cell markers (Spits
and Cupedo, 2012). ILCs are found at
mucosal sites, such as the gastrointes-
tinal tract and lung, where they respond
to tissue stress or infection by secreting
cytokines that promote innate immunity
and tissue repair, but which may also
contribute to immunopathology (Spits
and Cupedo, 2012). ILC subpopulations
are heterogeneous and have been classi-
fied according to their expression of key
transcription factors and effector cyto-kines, which mirror the polarization of
different CD4+ T helper subsets (Spits
et al., 2013; Spits and Cupedo, 2012).
Thus, ILC populations that express
GATA-3 and secrete T helper 2 (Th2) cell
related cytokines are termed ILC2,
whereas ILCs that express RORgt and
secrete Th17 or Th22 cell related cyto-
kines are termed ILC3 (Spits et al.,
2013). Until now, conventional natural
killer (NK) cells were regarded as the
innate cell Th1 doppelganger. However,
three recent studies (Bernink et al., 2013;
Fuchs et al., 2013; Klose et al., 2013),
including one in this issue of Immunity
(Fuchs et al., 2013), have identified
mucosal Th1 cell innate counterparts inhumans and mice. Termed ILC1, these
populations express the transcription fac-
tor T-bet and release IFN-g in response to
cytokines such as interleukin-12 (IL-12),
IL-15, and IL-18.
The search for novel human ILC popu-
lations was initially conducted on tonsil
samples.Within the CD56+CD3 cell frac-
tion, Fuchs et al. (2013) identified two
distinct populations (NKp44+CD103+ ILC
and NKp44CD103 ILC) that had the
capacity to secrete high amounts of
IFN-g, CCL4, and TNF-a in response to
the cytokines IL-12 and IL-15. Consistent
with their Th1-like profile, the ILC1
subsets expressed higher amounts of
T-bet and lower amounts of RORgt and
